Clinical trials
Lupus Erythematosus, Systemic clinical trials
Below are recruiting lupus erythematosus, systemic clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07005479Recruiting
Long-term lupus study at Peking University Hospital
This study looks at the long-term health of people with lupus. It aims to understand how the disease progresses over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07000110Recruiting
Anifrolumab and risk study for lupus patients
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
CopenhagenAges 18–130 - NCT06987565RecruitingPhase 2
Nerve stimulation device for lupus pain
This trial tests whether a non-invasive nerve stimulation device worn on the ear can help reduce pain and inflammation in people with lupus. It may be an option if you have moderate to severe muscle or joint pain and are not on certain medications that were recently started.
Manhasset, New YorkAges 18 years+ - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
San Francisco, CaliforniaAges 18–70 - NCT06892145RecruitingPhase 1
CAR-T cell therapy for tough systemic lupus
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
Hefei, AnhuiAges 18 years+ - NCT06880653Recruiting
Exercise dose study for arthritis pain
This study looks at how different amounts of exercise affect arthritis symptoms. If you have arthritis or a related condition, you may be asked to try a specific weekly exercise goal to see if it helps your pain and mobility.
Columbia, South CarolinaAges 18 years+ - NCT06795893Recruiting
Anifrolumab pregnancy outcomes study
This study collects information on pregnancy outcomes in women who took the drug anifrolumab during pregnancy or within 16 weeks before conception. It helps researchers understand how the drug may affect pregnancy and the baby.
SödertäljeAges Any age - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06659029Recruiting
Study on pregnancy outcomes in lupus patients using anifrolumab
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
Wilmington, North CarolinaAges Any age - NCT06647069RecruitingPhase 1
Testing a new drug for lupus and rheumatoid arthritis
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Melbourne, VictoriaAges 18–75 - NCT06594068RecruitingPhase 4
Anifrolumab in breastfeeding mothers with lupus
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
Las Vegas, NevadaAges 18–130 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT06465147RecruitingPhase 1
Cell therapy for hard-to-treat lupus (REACT-01)
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Seattle, WashingtonAges 2–30 - NCT06208514Recruiting
Brief Pain Exposure Therapy for chronic pain conditions
This study tests a type of talk therapy called Brief Pain Exposure Therapy (BPET) for people with certain chronic pain conditions like fibromyalgia, lupus, or chronic low back pain. It aims to help reduce pain by changing how your brain responds to it.
Ann Arbor, MichiganAges 18 years+ - NCT06189157RecruitingPhase 1/Phase 2
Testing MB-CART19.1 therapy for severe lupus
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
ErlangenAges 18 years+ - NCT06182969RecruitingPhase 1/Phase 2
APG-2575 for mild to moderate lupus
This trial tests an experimental drug called APG-2575 for people with mild to moderate lupus. It aims to see if the drug can help control lupus activity and improve symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05858684RecruitingEarly Phase 1
CAR-T therapy for hard-to-control lupus
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05567198Recruiting
Testing hormone shots to protect ovaries during lupus chemotherapy
This study looks at whether a monthly/3-month hormone medicine (a “GnRH shot”) can help protect ovaries in people with lupus who are treated with cyclophosphamide. It also compares this to lupus patients who do not receive the ovarian-protecting shot, using questionnaires to track outcomes.
Bethesda, MarylandAges 18–120 - NCT04833465Recruiting
Testing a new outcome measure in kids with rheumatology diseases
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Washington D.C., District of ColumbiaAges 5–21 - NCT04751396Recruiting
Melanoma education for people with autoimmune conditions
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Houston, TexasAges 18 years+ - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99 - NCT02422875Enrolling by invitation
Study of immune markers in autoimmune disease and lupus
This study looks at blood and immune cell markers (autoantibodies and immune cell “signatures”) to better understand autoimmune conditions, including lupus. It may help researchers identify which markers are linked to disease and how immune cells respond after vaccination.
Atlanta, GeorgiaAges 18 years+
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus, systemic?
- Yes. Clin2 currently lists 260 recruiting lupus erythematosus, systemic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus, systemic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus, systemic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.